维亚生物科技控股集团（01873）于2026年3月3日公布2026年2月截至月度的股份变动月报表。报告期内，公司法定股本依旧为4,000,000,000股，每股面值USD 0.000025，总额USD 100,000，较上月底无变化。
同时，公司已发行股本维持2,129,882,353股，未见新增发行、购回、注销或库藏股变动。有关公司期权方面，截至2026年2月底，“首次公开发售前股份奖励计划”与“首次公开发售后购股权计划”均未发生期权授出、行使或失效，数量分别保持在2,217,093份与18,020,000份，整体情况稳定。
公司声明已遵守香港联交所《上市规则》及相关法律规定，并确认当月所有证券发行及相关事宜均获正式授权。公告由执行董事毛晨签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.